



## ASX ANNOUNCEMENT

### **Actinogen Medical Conference Call**

**Sydney 30 September 2019: Actinogen Medical ASX: ACW ('ACW' or 'the Company')** will host a conference call at 10:30am (AEST) on Tuesday 1<sup>st</sup> October 2019.

During the call, Actinogen CEO and Managing Director Dr Bill Ketelbey will discuss recent clinical trial results, referred to in the Company's request for a Trading Halt (on Friday 27<sup>th</sup> September). An announcement regarding those results will be lodged with the ASX tomorrow morning, prior to the opening of trading and the conference call.

The Company invites participants to ask questions during the call. In addition, interested parties may submit questions prior to the call to [info@actinogen.com.au](mailto:info@actinogen.com.au).

Participants are encouraged to pre-register for the call here at:

<https://s1.c-conf.com/DiamondPass/Actinogen-invite.html>

Upon registration participants will receive a PIN and diary note for fast-track access to the call.

## ENDS

### **Actinogen Medical**

Dr. Bill Ketelbey  
CEO & Managing Director  
P: +61 2 8964 7401  
E: [bill.ketelbey@actinogen.com.au](mailto:bill.ketelbey@actinogen.com.au)  
 @BillKetelbey

### **Investor and Media Enquiries**

Arthur Chan  
WE Buchan  
M: +61 2 9237 2805  
E: [arthurc@we-buchan.com](mailto:arthurc@we-buchan.com)

### **About Actinogen Medical**

Actinogen Medical (ASX: ACW) is an ASX-listed biotechnology company focused on innovative approaches to treating cognitive decline that occurs in chronic neurological and metabolic diseases. Actinogen Medical is developing its lead compound Xanamem, as a promising new therapy for Alzheimer's disease, a condition with multibillion-dollar market potential and material human impact. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn and is projected to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia. In addition, Actinogen is currently planning an expanded clinical development program for Xanamem in cognitive impairment in mood disorders and schizophrenia. In the US alone, the collective economic costs of mood disorders and schizophrenia are estimated to exceed \$550bn, with the burden increasing every year. The cognitive dysfunction associated with these conditions is significantly debilitating for affected patients, with a substantial unmet medical need for novel, improved treatments.

### **About Xanamem™**

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. There is a strong association between chronic stress and excess cortisol that leads to changes in the

brain affecting memory. The 11 $\beta$ -HSD1 enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain associated with cognitive impairment in neurological diseases, including Alzheimer's disease, mood disorders and schizophrenia.

### **About XanADu**

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu has fully enrolled 186 patients from 25 research sites across Australia, the UK and the USA. The trial is registered on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

### **About XanaHES**

XanaHES is a Phase I, randomised, single blinded, central reader blinded, placebo-controlled, dose escalation study to assess the safety and tolerability of Xanamem™ 20mg & 30mg once daily in healthy elderly volunteers. Changes in cognitive performance from baseline to end-of-treatment will be measured as an exploratory efficacy outcome.

**Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.**